Reproductive Genetics Market Report 2025

The reproductive genetics market size has grown rapidly in recent years. It will grow from $6.83 billion in 2024 to $7.91 billion in 2025 at a compound annual growth rate (CAGR) of 15.8%. The growth in the historic period can be attributed to the increasing demand for in vitro fertilization (IVF) procedures, the rising prevalence of genetic disorders, the growing maternal age, expanding awareness of prenatal screening, and increasing government initiatives in genetic research.

The reproductive genetics market size is expected to see rapid growth in the next few years. It will grow to $14.07 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the growing adoption of assisted reproductive technologies (ART), the rising focus on personalized medicine, the increasing use of non-invasive prenatal testing (NIPT), the expansion of the fertility tourism market, and increasing investments in genetic counseling services. Major trends in the forecast period include advancements in genomic sequencing technologies, innovations in embryo screening techniques, developments in artificial intelligence (AI) for reproductive genetics, research and development in gene editing, and technological integration in fertility clinics.

The rising number of genetic disorders is expected to drive the growth of the reproductive genetics market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual's deoxyribonucleic acid, which may range from a single gene mutation to broader chromosomal defects. The increase in these disorders is contributing to the demand for reproductive genetic testing, as families seek early insights to reduce uncertainty, make informed reproductive decisions, and prevent the transmission of inherited conditions. Reproductive genetics plays a vital role in identifying and managing genetic disorders, helping families take preventive steps and reduce the risk of passing conditions to future generations. For example, in July 2024, Cystic Fibrosis Australia, a national consumer organization, reported that the number of individuals with Cystic Fibrosis in the Australian Cystic Fibrosis Data Registry rose from 3738 in 2022 to 3798 in 2023, marking a 1.6 percent increase. As a result, the rising occurrence of genetic disorders is expected to support the growth of the reproductive genetics market.

Leading companies in the reproductive genetics market are focusing on creating advanced methods such as comprehensive multi-trait embryo comparison to provide prospective parents with tools for more accurate and individualized embryo selection. Comprehensive multi-trait embryo comparison refers to the process of evaluating and ranking multiple embryos based on a broad spectrum of hereditary conditions and complex traits, offering more informed and personalized decision-making during in vitro fertilization. For instance, in June 2025, Nucleus Genomics Inc., a biotechnology company based in the United States, introduced Nucleus Embryo, a cutting-edge reproductive genetics platform that enables in vitro fertilization patients to assess and compare up to twenty embryos based on more than nine hundred hereditary conditions along with complex characteristics such as appearance, cognitive ability, and mental health through polygenic scoring. This development represents a significant advancement beyond traditional genetic screening, granting parents greater control in embryo selection and raising ethical discussions around genetic optimization and trait selection.

In January 2024, Natera Inc., a genetic testing and diagnostics company based in the United States, acquired health assets from Invitae Corporation for a total of fifty-two point five million dollars. This acquisition is intended to enhance Natera’s reproductive genetics offerings by incorporating Invitae’s non-invasive prenatal screening and carrier screening services, thereby improving support for both patients and healthcare professionals. Invitae Corporation is a genetic information company located in the United States that offers reproductive genetics services such as preimplantation genetic testing, carrier screening, and analysis related to miscarriage.

Major players in the reproductive genetics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Medicover AB, OPKO Health Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., The Cooper Companies Inc., Vitrolife AB, BillionToOne Inc., Sophia Genetics SA, Eurofins Genomics India Private Limited, Invitae Corporation, Igenomix, Gonagen GmbH, and Darwin AG.

North America was the largest region in the reproductive genetics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in reproductive genetics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the reproductive genetics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Reproductive genetics is a branch of genetics that studies how genetic factors influence reproduction and the transmission of hereditary traits. It focuses on the genetic makeup of individuals involved in reproduction, examining how genes and chromosomes affect fertility, conception, and embryo development. This field explores the role of inherited genetic variations and their impact on reproductive health, with the goal of improving understanding of the biological processes underlying human reproduction and heredity.

The main product types of reproductive genetics are kits, laboratory-developed tests (LDTs), and reagents and consumables. Kits refer to standardized diagnostic tools designed to detect genetic variations relevant to reproductive health. The technologies used include polymerase chain reaction (PCR), next-generation sequencing (NGS), in-situ hybridization (ISH), and microarray analysis. These tools are applied in the detection of aneuploidy, single-gene disorders, structural chromosomal abnormalities, and other conditions. They are used by a range of end users, including hospitals, diagnostic laboratories, fertility clinics, and research institutions.

The reproductive genetics market research report is one of a series of new reports that provides reproductive genetics market statistics, including the reproductive genetics industry global market size, regional shares, competitors with the reproductive genetics market share, detailed reproductive genetics market segments, market trends, and opportunities, and any further data you may need to thrive in the reproductive genetics industry. This reproductive genetics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The reproductive genetics market consists of revenues earned by entities by providing services such as infertility genetic testing, genetic counselling, genomic data interpretation, and risk assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The reproductive genetics market also includes sales of cryopreservation media, embryo biopsy tools, and lab information management systems (LIMS). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.